The fight against HIV remains one of the most remarkable success stories in modern medicine. Over the past four decades, a diagnosis that was once considered an absolute fatality has evolved into a highly manageable, chronic condition for those with access to treatment. Yet, despite these monumental strides, HIV continues to pose a major global public health challenge. While new infections have declined significantly compared to previous decades, the rate of progress has slowed, and steep barriers to both prevention and treatment persist for millions of people worldwide.

Enter lenacapavir (marketed as Yeztugo® for prevention and Sunlenca® for treatment). This novel medication has generated considerable excitement within the global medical community. The U.S. Food and Drug Administration (FDA) approved lenacapavir as the first twice-yearly injectable option for HIV pre-exposure prophylaxis (PrEP), offering six full months of continuous protection with just a single subcutaneous dose.(1)

To appreciate the true significance of this milestone, it helps to look at the current state of the epidemic, the limitations of our traditional tools, and how lenacapavir directly solves some of the most stubborn challenges in HIV care.

The Current Landscape: HIV Epidemiology

The scale of the global HIV epidemic remains vast, with nearly 40 million people living with the virus. While new infections are down from their historic peaks, over 1.3 million people still contract HIV every single year.

This burden is not felt equally. South Africa, for example, is home to the world's largest HIV treatment program and one of the largest populations of people living with HIV. Despite remarkable progress in expanding antiretroviral therapy (ART), the country still records thousands of new infections annually.

Certain groups face a highly disproportionate risk. In sub-Saharan Africa, adolescent girls and young women account for a staggering majority of new infections. Globally, marginalized groups—including men who have sex with men (MSM), transgender individuals, and people who inject drugs—face high transmission rates coupled with steep socioeconomic barriers to accessing consistent healthcare.

The Traditional Arsenal: Current Modalities and PrEP

In recent years, countries like South Africa have made incredible strides toward the UNAIDS 95-95-95 targets (ensuring 95% of people living with HIV know their status, 95% of those diagnosed are on treatment, and 95% of those on treatment achieve viral suppression). However, stubborn gaps remain across the prevention and treatment pipeline.

For decades, the gold standard of care has relied on daily oral medication:

  • For Treatment: Individuals living with HIV take a combination of daily antiretroviral drugs to suppress viral replication. When taken consistently, the virus becomes undetectable in the bloodstream. Crucially, patients who maintain an undetectable viral load cannot sexually transmit the virus to others—a medical breakthrough known as Undetectable = Untransmittable (U=U).
  • For Prevention (PrEP): Pre-exposure prophylaxis allows HIV-negative individuals at high risk to prevent the virus from taking hold before an exposure occurs. Traditional PrEP relies on daily pills like Truvada® or Descovy®. While long-acting injectable cabotegravir (given every two months) recently expanded these options, it still requires frequent clinic visits.(2)

The "Adherence Challenge"

Although daily oral PrEP can reduce the risk of HIV acquisition by approximately 99% when taken consistently, its effectiveness in real-world settings depends heavily on adherence.

Taking medication every day requires a reliable routine, stable access to healthcare services, and regular prescription refills. For many individuals, these requirements can be difficult to maintain.

In addition, HIV-related stigma remains a significant barrier. Carrying or taking medication associated with HIV prevention may expose individuals to unwanted questions or social judgment, leading some to miss doses or discontinue treatment altogether.

As a result, researchers and public health experts have increasingly focused on long-acting prevention strategies that reduce the burden of daily adherence.

What Exactly is Lenacapavir?

Lenacapavir is the first approved member of a brand-new class of HIV medications called capsid inhibitors.

Traditional antiretroviral drugs target viral enzymes (like reverse transcriptase, protease, or integrase) after the virus has already heavily integrated into the host cell. Lenacapavir works entirely differently. It targets the HIV capsid—the protective protein shell that shields the virus's genetic material.(2)

By binding directly to this protective shell, lenacapavir acts like a wrench in the gears across multiple stages of the viral life cycle. It interferes with viral entry, prevents transport into the cell nucleus, disrupts replication, and stalls the assembly of new viral particles.

Because it attacks the virus so robustly from multiple angles, it maintains intense antiviral activity at remarkably low concentrations in the body. Paired with an exceptionally slow, steady release from subcutaneous tissue, a single injection provides continuous protection for up to six months.

Why Lenacapavir Matters

A. Near-Complete Protection in Clinical Trials

Lenacapavir's approval for HIV prevention was supported by two landmark clinical trials: PURPOSE 1 and PURPOSE 2.

  • PURPOSE 1 evaluated thousands of adolescent girls and young women in South Africa and Uganda. Among participants who received lenacapavir, no HIV infections were recorded during the study period, demonstrating exceptional efficacy.
  • PURPOSE 2 enrolled gay and bisexual men, transgender individuals, and gender-diverse participants across multiple countries. The study demonstrated approximately 99.9% efficacy and showed that lenacapavir substantially reduced HIV acquisition compared with background incidence rates and daily oral PrEP regimens.(2)

The results were so compelling that independent monitoring committees recommended early modification of the studies to allow broader participant access to the intervention.

B. Addressing Barriers to Adherence

Lenacapavir completely changes the lifestyle dynamics of HIV prevention. Swapping 365 daily pills (or six clinic visits a year for bi-monthly injections) for just two injections a year simplifies everything. It eliminates the risk of missed doses and offers total privacy for individuals with demanding schedules, unstable living conditions, or deep concerns about community stigma. For many individuals, this convenience could translate into sustained protection and improved long-term engagement with prevention services.(3)

Expanding Options for Drug-Resistant HIV

Beyond prevention, lenacapavir also plays an important role in HIV treatment. Under the brand name Sunlenca®, it is approved for use in heavily treatment-experienced individuals with multidrug-resistant HIV. For patients whose virus has developed resistance to multiple antiretroviral drug classes, lenacapavir provides a valuable new mechanism of action and an additional treatment option when alternatives may be limited.

The Next Frontier: Ensuring Global Access

Lenacapavir represents one of the most promising advances in HIV prevention in recent years. However, scientific innovation alone is insufficient if those who need it most cannot access it.

In high-income countries, the annual cost of lenacapavir remains substantial, creating concerns about affordability and equitable distribution. These concerns are even more pronounced in low- and middle-income countries (LMICs), where the burden of HIV remains highest.(4)

To address this challenge, voluntary licensing agreements have been established with generic manufacturers, with the goal of significantly reducing costs and expanding access across more than 100 countries. International agencies, governments, advocacy organisations, and pharmaceutical partners are now working to accelerate production, strengthen distribution systems, and ensure that the benefits of this breakthrough reach communities most affected by HIV.

Lenacapavir proves that the future of global HIV care no longer needs to hang on the fragile hook of daily pill adherence. If deployed smoothly and equitably at scale, this breakthrough tool could finally break the back of the global epidemic.

References:

  1. Gilead Sciences Inc. Yeztugo® (Lenacapavir) Is Now the First and Only FDA Approved HIV Prevention Option Offering 6 Months of Protection 2025 [04 June 2026]. Available from: https://www.gilead.com/news/news-details/2025/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months-of-protection.
  2. Miteu GD. Lenacapavir and global HIV prevention: a breakthrough at risk of leaving millions behind. Ann Med Surg (Lond). 2026;88(3):2462-6.
  3. Connolly L. Lenacapavir approved by FDA: What it means for HIV prevention 2025 [1 July 2025]. Available from: https://health.ucdavis.edu/children/news/headlines/lenacapavir-approved-by-fda-what-it-means-for-hiv-prevention-/2025/07.
  4. UNAIDS. UNAIDS calls on leaders at Davos to commit to rapid global access to revolutionary new long-acting HIV medicines 2025 [21 Janauary 2025]. Available from: https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2025/january/20250121_davos.

 

Photo credit – KABOOMPICS on Pexels: https://www.pexels.com/photo/close-up-of-holding-a-syringe-while-wearing-blue-gloves-5207022/